JZP-110: Ph II started

Jazz began a 4-week, double-blind, placebo-controlled, crossover, U.S. Phase II trial to evaluate 75, 150 and 300 mg doses of oral JZP-110 in about 50 PD patients. Top-line data from a pair of Phase I...